Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A survey of palivizumab for infants with cystic fibrosis in the UK.

× No keyword cloud information.

2 in total

1. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

Authors:
Journal: Pediatrics Date: 1998-09 Impact factor: 7.124

2. Immunisation in the current management of cystic fibrosis patients.

Authors: Anne Malfroot; Georgios Adam; Oana Ciofu; Gerd Döring; Christiane Knoop; Aloïs B Lang; Pierre Van Damme; Isi Dab; Andrew Bush
Journal: J Cyst Fibros Date: 2005-05 Impact factor: 5.482

2 in total

9 in total

Review 1. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

Authors: Karen A Robinson; Olaide A Odelola; Ian J Saldanha
Journal: Cochrane Database Syst Rev Date: 2016-07-20

2. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors: Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal: Can Respir J Date: 2011 Mar-Apr Impact factor: 2.409

3. Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis.

Authors: Mukta Jain; Anne H Thomson
Journal: J R Soc Med Date: 2009-07 Impact factor: 5.344

4. Respiratory Syncytial Virus Prophylaxis in Special Populations: Is it Something Worth Considering in Cystic Fibrosis and Immunosuppression?

Authors: William A Prescott; David J Hutchinson
Journal: J Pediatr Pharmacol Ther Date: 2011-04

5. The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.

Authors: Ashleigh A McGirr; Kevin L Schwartz; Upton Allen; Melinda Solomon; Beate Sander
Journal: Hum Vaccin Immunother Date: 2016-10-21 Impact factor: 3.452

A survey of palivizumab for infants with cystic fibrosis in the UK.

1. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.

2. Immunisation in the current management of cystic fibrosis patients.

Review 1. Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis.

2. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

3. Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis.

4. Respiratory Syncytial Virus Prophylaxis in Special Populations: Is it Something Worth Considering in Cystic Fibrosis and Immunosuppression?

5. The cost-effectiveness of palivizumab in infants with cystic fibrosis in the Canadian setting: A decision analysis model.

6. Respiratory hospitalizations and respiratory syncytial virus prophylaxis in special populations.

7. Anti-RSV prophylaxis efficacy for infants and young children with cystic fibrosis in Ireland.

8. Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV).

9. Palivizumab immunoprophylaxis effectiveness in children with cystic fibrosis.